Browsing by Author "Koay, Eugene J."

Now showing 1 - 2 of 2
  • No Thumbnail Available
    Item
    Defining Minimum Treatment Parameters of Ablative Radiation Therapy in Patients With Hepatocellular Carcinoma: An Expert Consensus
    (2024) Yanagihara, Ted K.; Tepper, Joel E.; Moon, Andrew M.; Barry, Aisling; Molla, Meritxell; Seong, Jinsil; Torres, Ferran; Apisarnthanarax, Smith; Buckstein, Michael; Cardenes, Higinia; Chang, Daniel T.; Feng, Mary; Guha, Chandan; Hallemeier, Christopher L.; Hawkins, Maria A.; Hoyer, Morten; Iwata, Hiromitsu; Jabbour, Salma K.; Kachnic, Lisa; Kharofa, Jordan; Kim, Tae Hyun; Kirichenko, Alexander; Koay, Eugene J.; Makishima, Hirokazu; Mases, Joel; Meyer, Jeffrey J.; Munoz-Schuffenegger, Pablo; Owen, Dawn; Park, Hee Chul; Saez, Jordi; Sanford, Nina N.; Scorsetti, Marta; Smith, Grace L.; Wo, Jennifer Y.; Yoon, Sang Min; Lawrence, Theodore S.; Reig, Maria; Dawson, Laura A.
    Purpose: External beam radiation therapy (EBRT) is a highly effective treatment in select patients with hepatocellular carcinoma (HCC). However, the Barcelona Clinic Liver Cancer system does not recommend the use of EBRT in HCC due to a lack of sufficient evidence and intends to perform an individual patient level meta -analysis of ablative EBRT in this population. However, there are many types of EBRT described in the literature with no formal definition of what constitutes "ablative." Thus, we convened a group of international experts to provide consensus on the parameters that define ablative EBRT in HCC. Methods and Materials: Fundamental parameters related to dose, fractionation, radiobiology, target identification, and delivery technique were identified by a steering committee to generate 7 Key Criteria (KC) that would define ablative EBRT for HCC. Using a modified Delphi (mDelphi) method, experts in the use of EBRT in the treatment of HCC were surveyed. Respondents were given 30 days to respond in round 1 of the mDelphi and 14 days to respond in round 2. A threshold of >= 70% was used to define consensus for answers to each KC. Results: Of 40 invitations extended, 35 (88%) returned responses. In the first round, 3 of 7 KC reached consensus. In the second round, 100% returned responses and consensus was reached in 3 of the remaining 4 KC. The distribution of answers for one KC, which queried the a/b ratio of HCC, was such that consensus was not achieved. Based on this analysis, ablative EBRT for HCC was defined as a BED10 >= 80 Gy with daily imaging and multiphasic contrast used for target delineation. Treatment breaks (eg, for adaptive EBRT) are allowed, but the total treatment time should be <= 6 weeks. Equivalent dose when treating with protons should use a conversion factor of 1.1, but there is no single conversion factor for carbon ions. Conclusions: Using a mDelphi method assessing expert opinion, we provide the first consensus definition of ablative EBRT for HCC. Empirical data are required to define the a/b of HCC. (c) 2023 Published by Elsevier Inc. on behalf of American Society for Radiation Oncology.
  • Thumbnail Image
    Item
    RNA. sequencing-based analysis of gallbladder cancer reveals the importance of the liver X. receptor and lipid metabolism in gallbladder cancer
    (2016) Zuo, Mingxin; Rashid, Asif; Wang, Ying; Jain, Apurva; Li, Donghui; Behari, Anu; Kapoor, Vinay Kumar; Koay, Eugene J.; Chang, Ping; Roa Strauch, Juan Carlos Enrique; Vauthey, Jean Nicholas; Li, Yanan; Espinoza, Jaime A.; Javle, Milind